Although direct evidence that Th-2 cells can suppress anti-tumor immunity and promote tumor progression is lacking for TLSs, findings regarding the TME suggest that Th2 cells can produce IL-4 and IL-13, with the former increasing the expression of epidermal growth factor to enhance neoplastic extravasating into the circulation, and the latter inhibiting the CD8+ cytotoxic T cell (CTL) response indirectly by increasing TGF-β production by myeloid cells in the tumor [54,55]. The gene discussed is IL4; the disease is neoplasm.